When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BYND - AIMT Remains Undervalued Before FDA Decision On Palforzia
Beyond Meat Inc.
Aimmune Therapeutics, Inc. (AIMT) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. But even at current levels, the company is significantly undervalued and has room to increase above $60 in the coming year.
What is Palforzia? Who is it for? How is it administered?
AIMT is seeking FDA approval for Palforzia to treat patients with peanut allergies ages 4-17.